Clinical trials
Atherosclerosis trials in the United Kingdom with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Unknown status | 5 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| St George's, University of London | 3 |
| Boston Scientific Corporation | 2 |
| Cambridge University Hospitals NHS Foundation Trust | 2 |
| Abbott Medical Devices | 1 |
| Amgen | 1 |
| Imperial College London | 1 |
| Liverpool John Moores University | 1 |
| Medstar Health Research Institute | 1 |
| Medtronic Endovascular | 1 |
| Sheffield Teaching Hospitals NHS Foundation Trust | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Atherosclerosis | 18 |
| Coronary Artery Disease | 4 |
| Cardiovascular Diseases | 3 |
| Inflammation | 3 |
| Arterial Occlusive Diseases | 1 |
| Arteriosclerosis | 1 |
| Carotid Stenosis | 1 |
| Coronary Stenosis | 1 |
| Coronary Vasospasm | 1 |
| Diabetes Mellitus | 1 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.